With a market capitalization (market cap) of $16.48B — a measure of how much the company is worth — Medpace Holdings, Inc. is the 695th most valuable company in Healthcare as of August 18, 2026. Shares trade at $590.30, down +1.14% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Visit websiteAs of August 18, 2026, Medpace Holdings, Inc. (MEDP) is worth $16.48B — this is its market capitalization, the total value of all its outstanding shares.
Medpace Holdings, Inc.’s market cap is $16.48B, which ranks it #695 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Medpace Holdings, Inc. (MEDP) shares trade at $590.30, down 1.14% on the day, as of August 18, 2026.
Medpace Holdings, Inc. trades at a price-to-earnings (P/E) ratio of 37.7, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025